טוען...
Investigational Drug Treatments for Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) and accounts for 10–20% of cases. Due to the lack of expression of several receptors, hormone therapy is largely ineffective for treatment purposes. Nevertheless, TNBC often responds very well to chemotherapy, which...
שמור ב:
| הוצא לאור ב: | J Pers Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8303312/ https://ncbi.nlm.nih.gov/pubmed/34357119 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm11070652 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|